
Arrowhead Pharmaceuticals Inc
ARWRHealthcare|Biotechnology|USA
$59.50
-1.62 (-2.65%)
Tangible Book
$4.09
Graham Number
$11.87
Clinical Trials (71)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06822790 Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | Hypertriglyceridemia | P3 | Recruiting | 869 | Open-label | Plozasiran Injection |
| NCT06366698 Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia | Iron Deficiency Anemia of Pregnancy | P3 | Recruiting | 900 | RCT, Open-label | Venofer 200 MG Per 10 ML Injection, Ferrous sulfate |
| NCT03936361 Statins In Intracerbral Hemorrhage | Intracerebral Hemorrhage | P3 | Recruiting | 1,456 | RCT, Single-blind | Statins |
| NCT06347003 Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | P3 | Active | 446 | RCT, Double-blind | Plozasiran Injection, Placebo |
| NCT06347016 Study of Plozasiran in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | P3 | Active | 311 | RCT, Double-blind | Plozasiran Injection, Placebo |
| NCT06347133 Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | Hypertriglyceridemia | P3 | Active | 1,456 | RCT, Double-blind | Plozasiran Injection, Placebo |
| NCT05089084 Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | Familial Chylomicronemia | P3 | Active | 75 | RCT, Double-blind | Plozasiran, Placebo |
| NCT07037771 A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | Homozygous Familial Hypercholesterolemia | P3 | Recruiting | 60 | RCT, Double-blind | zodasiran Injection, Placebo |
| NCT06880770 Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | Severe Hypertriglyceridemia | P3 | Recruiting | 288 | RCT, Double-blind | Plozasiran, Placebo |
| NCT07221344 Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease | Alzheimer Disease, Alzheimer Disease, Early Onset | P1P2 | Recruiting | 112 | RCT, Double-blind | ARO-MAPT-SC, Placebo |
| NCT06700538 Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus | Obesity | P1P2 | Recruiting | 120 | RCT, Double-blind | ARO-INHBE, Placebo, Tirzepatide |
| NCT06131983 Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1 | Facio-Scapulo-Humeral Dystrophy | P1P2 | Recruiting | 60 | RCT, Double-blind | ARO-DUX4 for Injection, Placebo |
| NCT07223658 Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | Hyperlipidemia; Mixed | P1P2 | Recruiting | 78 | RCT, Double-blind | ARO-DIMERPA, Placebo |
| NCT06138743 Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy | Myotonic Dystrophy 1 | P1P2 | Recruiting | 78 | RCT, Double-blind | ARO-DM1 Intravenous (IV) Infusion, Placebo Intravenous (IV) Infusion, ARO-DM1 subcutaneous (SC) injection, Placebo Subcutaneous (SC) Injection |
| NCT06937203 Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus | Obesity, Diabetes Mellitus, Type 2 | P1P2 | Recruiting | 126 | RCT, Double-blind | ARO-ALK7, Placebo |
| NCT05217667 Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) | Homozygous Familial Hypercholesterolemia | P2 | Active | 18 | RCT, Open-label | ARO-ANG 3 Injection |
| NCT06209177 Study of ARO-CFB in Adult Healthy Volunteers | IgA Nephropathy | P1 | Active | 49 | RCT, Double-blind | ARO-CFB, Placebo |
| NCT06543290 Azithromycin Before Induction | Infections | P1 | Recruiting | 400 | RCT, Double-blind | Azithromycin Pill, Placebo |
| NCT06672445 Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 2 | P1 | Recruiting | 36 | RCT, Double-blind | ARO-ATXN2 Injection, Placebo |
| NCT06827288 Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder | Opioid Use Disorder | N/A | Recruiting | 500 | RCT, Open-label | — |
| NCT02299414 Chronic Hypertension and Pregnancy (CHAP) Project | Hypertension | P4 | Completed | 2,408 | RCT, Open-label | Anti-hypertensive therapy |
| NCT01736449 Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management | Pterygium | P4 | Completed | 31 | RCT, Open-label | Bevacizumab |
| NCT03469947 California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA | Hemorrhagic Shock, Trauma Injury | P3 | Completed | 200 | Open-label | Tranexamic Acid |
| NCT05902598 A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome | Familial Chylomicronemia Syndrome | P3 | Completed | 37 | RCT, Double-blind | Plozasiran, Placebon |
| NCT07056062 Oral Calcium Supplementation in Labor | Uterine Contraction, Labor Complication | P2P3 | Completed | 89 | RCT, Open-label | Calcium carbonate |
| NCT07473843 Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia | Homozygous Familial Hypercholesterolemia | P3 | Not Yet Recruiting | 12 | Open-label | Zodasiran |
| NCT04375514 Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis | Cystic Fibrosis, Pulmonary | P1P2 | Terminated | 43 | RCT, Double-blind | ARO-ENaC, Placebo |
| NCT02604212 A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection | Hepatitis B | P2 | Terminated | 32 | RCT, Double-blind | ARC-520, entecavir, antihistamine, tenofovir |
| NCT03365947 Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) | Hepatitis B | P1P2 | Completed | 114 | RCT, Double-blind | ARO-HBV, JNJ-56136379 |
| NCT05083364 Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease | C3 Glomerulopathy, IgA Nephropathy | P1P2 | Completed | 62 | RCT, Double-blind | ARO-C3, Placebo |
| NCT04998201 Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia | Mixed Dyslipidemia | P2 | Completed | 353 | RCT, Double-blind | ARO-APOC3, Placebo |
| NCT07241546 Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma | Asthma | P2 | Not Yet Recruiting | 36 | RCT, Double-blind | ARO-RAGE, Placebo |
| NCT04832971 Study of ARO-ANG3 in Adults With Mixed Dyslipidemia | Mixed Dyslipidemia | P2 | Completed | 204 | RCT, Double-blind | ARO-ANG3, Placebo |
| NCT02452528 Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus | Chronic Hepatitis B | P2 | Terminated | 4 | RCT, Double-blind | ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine |
| NCT05537025 Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | P1P2 | Completed | 105 | RCT, Double-blind | ARO-MMP7 Inhalation Solution, Placebo |
| NCT02349126 Study of ARC-520 in Patient With Chronic Hepatitis B Virus | Chronic Hepatitis B | P2 | Withdrawn | — | Open-label | ARC-520 Injection |
| NCT02604199 A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection | Hepatitis B | P2 | Terminated | 58 | RCT, Double-blind | ARC-520 Injection, entecavir, tenofovir, antihistamine |
| NCT05276570 Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease | Asthma | P1P2 | Completed | 127 | RCT, Double-blind | ARO-RAGE, Placebo |
| NCT04202354 Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH | Non-alcoholic Steatohepatitis | P1P2 | Completed | 50 | RCT, Double-blind | ARO-HSD Injection, sterile normal saline (0.9% NaCl) |
| NCT03946449 Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD) | Alpha 1-Antitrypsin Deficiency | P2 | Completed | 16 | Open-label | ARO-AAT |
| NCT05292950 Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease | Asthma, Chronic Obstructive Pulmonary Disease | P1P2 | Terminated | 78 | RCT, Double-blind | ARO-MUC5AC, Placebo |
| NCT02738008 Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection | Hepatitis B | P2 | Terminated | 12 | Open-label | ARC-520 Injection, entecavir, tenofovir, antihistamine |
| NCT02577029 Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) | Hepatitis B, Hepatitis D | P2 | Terminated | 79 | Open-label | ARC-520, entecavir, pegylated interferon alpha 2a, tenofovir disoproxil, antihistamine |
| NCT02900183 Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels | Alpha-1 Antitrypsin Deficiency | P2 | Withdrawn | — | Open-label | ARC-AAT Injection |
| NCT05413135 Study of ARO-APOC3 in Adults With Dyslipidemia | Dyslipidemias | P2 | Completed | 418 | Open-label | ARO-APOC3 |
| NCT04720534 Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia | Severe Hypertriglyceridemia | P2 | Completed | 229 | RCT, Double-blind | ARO-APOC3, Placebo |
| NCT02065336 A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection | Hepatitis B, Chronic | P2 | Terminated | 58 | RCT, Double-blind | ARC-520, Placebo, entecavir, chlorpheniramine |
| NCT03945292 Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) | Alpha 1-Antitrypsin Deficiency | P2 | Completed | 40 | RCT, Double-blind | Fazisiran Injection |
| NCT03747224 Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients | Dyslipidemias, Familial Hypercholesterolemia | P1 | Completed | 93 | RCT, Double-blind | ARO-ANG3, sterile normal saline (0.9% NaCl) |
| NCT02797522 A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) | Hepatitis B | P1 | Terminated | 47 | RCT, Double-blind | ARC-521 Injection, antihistamine, acetaminophen, entecavir, tenofovir |
| NCT05533294 Study of ARO-RAGE in Healthy Subjects | Asthma | P1 | Completed | 43 | RCT, Double-blind | ARO-RAGE Injection, Placebo |
| NCT05757596 Study of VSA001 Injection in Chinese Healthy Adult Volunteers | Healthy Adult Volunteers | P1 | Completed | 24 | RCT, Double-blind | VSA001 injection, Placebo |
| NCT03362242 Study of ARO-AAT in Normal Adult Volunteers | Alpha 1-Antitrypsin Deficiency | P1 | Completed | 45 | RCT, Double-blind | ARO-AAT Injection |
| NCT03783377 Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) | Hypertriglyceridemia, Familial Chylomicronemia | P1 | Completed | 112 | RCT, Double-blind | ARO-APOC3, sterile normal saline (0.9% NaCl) |
| NCT02363946 A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) | Alpha-1 Antitrypsin Deficiency | P1 | Terminated | 65 | RCT, Double-blind | ARC-AAT Injection, Diphenhydramine |
| NCT02535416 A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers | Healthy | P1 | Completed | 40 | Open-label | ARC-520, cetirizine, diphenhydramine |
| NCT04169711 Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | P1 | Completed | 26 | Open-label | ARO-HIF2 |
| NCT01872065 Safety and Tolerability Study of ARC-520 in Healthy Volunteers | Healthy | P1 | Completed | 54 | RCT, Double-blind | ARC-520, Placebo |
| NCT05949294 Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P1 | Withdrawn | — | Open-label | ARO-SOD1 Injection |
| NCT05400382 Mindfulness to Reduce Post-cesarean Pain and Prevent Postpartum Depression | Depression, Unipolar, Pain, Postoperative | N/A | Unknown | 75 | RCT, Open-label | — |
| NCT01465516 Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir | Hepatitis C Infection | Terminated | 105 | — | Boceprevir | |
| NCT06402669 Extremity Trauma At a Level 1 Trauma Center | Trauma Injury, Trauma Blunt | Completed | 20,000 | — | — | |
| NCT02485262 Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience | Hepatitis C | Unknown | 340 | — | Sofosbuvir and simeprevir | |
| NCT05897528 Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection | COVID-19, Diabetes Mellitus | Completed | 589 | — | — | |
| NCT06796426 Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS | Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG) | AVAILABLE | — | — | Plozasiran | |
| NCT05888363 Management and Removal of Foreign Bodies in the Emergency Department | Rectal Foreign Body, Rectal Perforation | Completed | 78 | — | — | |
| NCT05964088 Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients | Acute Kidney Injury | Completed | 267 | — | — | |
| NCT05611398 Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention | Lactate Blood Increase, Trauma Blunt | Completed | 164 | — | — | |
| NCT05859958 ABO Blood Group Type Association With COVID-19 Severity | COVID-19, Blood Group Antigen Abnormality | Completed | 599 | — | — | |
| NCT05612867 Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C | Burns, Ascorbic Acid Deficiency | Completed | 54 | — | — | |
| NCT05611385 Amphetamine Induced Adult Respiratory Distress Syndrome | Burns, Acute Lung Injury | Completed | 49 | — | — |